Restless legs syndrome drug approved

US regulators have approved XenoPort Inc's drug Horizant to treat restless legs syndrome (RLS).

Horizant, developed with partner GlaxoSmithKline Plc, is a long-lasting version of gabapentin.

In February 2010, the US Food and Drug Administration declined to approve Horizant, raising concerns about a pancreatic cancer signal seen in rats at very high doses.

The FDA has asked the company to conduct a number of post-marketing studies, focusing mainly on the potential for driving impairment.

Up to 10% of the US population may have RLS, according to the National Institute of Neurological Disorders and Stroke (NINDS).

Some industry analysts believe Horizant will face stiff competition from the products currently being used to treat RLS generic agents Requip and Mirapex, and off-label gabapentin usage.

XenoPort is also developing Horizant for post-herpetic neuralgia and some see a limited market there as well given that gabapentin itself is approved as a cure.

(Reuters Health,Shravya Jain, April 2011)

Read more:

Restless leg syndrome and heart issues

Restless legs linked to fibromyalgia

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Voting Booth
Have you entered our Health of the Nation survey?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes
33% - 9320 votes
No
67% - 18608 votes
Vote